Schwab Schwab N N Schneider-Hohendorf Schneider-Hohendorf T T Wiendl Wiendl H H CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients Neurology Neurology 2016 2016 87 87 9 9 958 958 959 959 10.1212/01.wnl.0000496643.57775.41 10.1212/01.wnl.0000496643.57775.41 supplied-pmid 27572431? This evidence concerns the gene SELL and myeloid sarcoma.